


Roche and Genentech Spinal Muscular Atrophy Clinical Development Program


F Petridis¹, K Gorni¹, K Gelblin¹, R Scalco¹, F Warren¹, L Burke¹, J Baird², Naryshkin N², K Chen³, K Howell³, Y Qian³

1. Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; 2. PTC Therapeutics Ltd, New Jersey, USA; 3. SMA Foundation, New York, USA

Roche and Genentech are developing and testing **risdiplam (EVRYSDI™)**, an oral medicine which has been approved by the Food and Drug Administration (FDA) for the treatment of patients with SMA, aged 2 months and older.¹ According to preclinical data, risdiplam is distributed throughout the body.² Risdiplam is a SMN2 splicing modifier and is being developed in collaboration with the SMA Foundation and PTC Therapeutics.



Current status of risdiplam clinical study program



*This poster contains general information about our SMA program and is not intended as specific medical advice and should not be construed as a recommendation for the use of any product for unapproved uses. Risdiplam has only been approved by the US FDA for the treatment of patients with SMA, aged 2 months and older. This compound and its use may not be approved in your country. You should talk with your healthcare provider for information and advice about your condition, including any current or potential treatments.

[†]Final participant study numbers; [‡]Numbers of participants based on planned enrollment. [§]Data cut off: 31 Jan 2020.

References

1. EVRYSDI™ prescribing information: https://www.gene.com/download/pdf/evrydsi_prescribing.pdf (Accessed November 2020); 2. Poirier A, et al. Pharmacol Res Perspect. 2018; 29:1–12; 3. Clinicaltrials.gov. NCT02913482 (Accessed November 2020); 4. Baranello G, et al. Data presented at Myology 2019; 5. Clinicaltrials.gov. NCT02908685 (Accessed November 2020); 6. Mercuri E, et al. Data presented at Myology 2019; 7. Clinicaltrials.gov. NCT03032172 (Accessed November 2020); 8. CA Chiriboga, et al. Data presented at WMS 2020; 9. Clinicaltrials.gov. NCT03779334 (Accessed November 2020); 10. Baranello G, et al. Data presented at WMS 2020; 11. Day JW, et al. Data presented at WMS 2020; 12. Bertini E, et al. Data presented at Myology 2019.

Acknowledgments

We thank our collaborators and participants who take part in our clinical trials. The logos are the property of the companies listed. Editorial support was provided by Lauren Walmsley, PhD, of MediTech Media UK, funded by F. Hoffmann-La Roche Ltd. Genentech is a member of the Roche group.

M-XX-00001681